Search results for "Neoplastic"

showing 10 items of 2901 documents

A Molecular Electron Density Theory Study of the Chemoselectivity, Regioselectivity, and Diastereofacial Selectivity in the Synthesis of an Anticance…

2019

The [3 + 2] cycloaddition (32CA) reaction of an &alpha

Models Molecular[3 + 2] cycloaddition reactionsDouble bondNitrilePharmaceutical ScienceAntineoplastic Agentsdiastereofacial selectivityArticleAnalytical Chemistrylcsh:QD241-441chemistry.chemical_compoundlcsh:Organic chemistryComputational chemistryDrug DiscoveryReactivity (chemistry)Physical and Theoretical ChemistryChemoselectivitychemistry.chemical_classificationCycloaddition ReactionMolecular StructureOrganic Chemistrymolecular electron density theoryRegioselectivityStereoisomerismIsoxazolesCycloadditionα-santoninchemistryChemistry (miscellaneous)regioselectivitynitrile oxidesMolecular MedicineDensity functional theorySantoninDerivative (chemistry)Molecules
researchProduct

Palladium(II)-Stabilized Pyridine-2-Diazotates: Synthesis, Structural Characterization, and Cytotoxicity Studies

2018

Well-defined diazotates are scarce. Here we report the synthesis of unprecedented homoleptic palladium(II) diazotate complexes. The palladium(II)-mediated nitrosylation of 2-aminopyridines with NaNO2 results in the formation of metal-stabilized diazotates, which were found to be cytotoxic to human ovarian cancer cells.

Models Molecularinorganic chemicalsCell SurvivalPyridinesPyrazine Diazohydroxidechemistry.chemical_elementAntineoplastic AgentsorganometalliyhdisteetCrystallography X-Ray010402 general chemistry01 natural sciencesInorganic ChemistryStructure-Activity Relationshipchemistry.chemical_compoundCoordination ComplexesCell Line Tumororganometallic compoundsPyridineHumansCytotoxic T cellsytotoksisuusPhysical and Theoretical ChemistryHomolepticCytotoxicityta116Cell ProliferationDose-Response Relationship DrugMolecular Structure010405 organic chemistryNitrosylationCombinatorial chemistry0104 chemical sciencesHEK293 Cellssyöpäsolutchemistrycancer cellsOvarian cancer cellscytotoxicityDrug Screening Assays AntitumorAzo CompoundsPalladiumPalladiumInorganic Chemistry
researchProduct

Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor…

2011

A shot in the arm for cancer treatment: two MUC1 tetanus toxoid vaccines were synthesized and induced a strong immune response in mice. The antibodies elicited by the vaccines show a high selectivity for the tumor cells in mammary carcinoma tissues and also distinguish between tumor tissues at different stages.

Molecular ConformationAntineoplastic AgentsBreast Neoplasmscomplex mixturesCancer VaccinesCatalysisBreast tumorMiceImmune systemmedicineAnimalsMUC1Mice Inbred BALB CVaccines SyntheticbiologyTetanusChemistryMucin-1ToxoidGlycopeptidesMammary Neoplasms ExperimentalGeneral Chemistrymedicine.diseaseGlycopeptideCancer researchbiology.proteinMCF-7 CellsExperimental pathologyFemaleAntibodyDrug Screening Assays AntitumorAngewandte Chemie (International ed. in English)
researchProduct

Stereoselective Synthesis of the Cytotoxic Macrolide FD-891

2006

[reaction: see text] A total synthesis of the naturally occurring, cytotoxic macrolide FD-891 is described. Three fragments were first stereoselectively constructed using mainly asymmetric aldol and allylation reactions. The complete framework was then assembled using two Julia-Kocienski olefinations to connect the three fragments and a Yamaguchi reaction to close the macrolactone ring.

Molecular StructureChemistryStereochemistryOrganic ChemistryTotal synthesisAntineoplastic AgentsStereoisomerismGeneral MedicineRing (chemistry)BiochemistryAldol reactionCytotoxic T cellStereoselectivityMacrolidesPhysical and Theoretical ChemistryOrganic Letters
researchProduct

Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive b…

2021

Abstract Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico desi…

Molecular dynamicAntineoplastic Agents Hormonalmedicine.drug_classIn silicoEstrogen receptorBreast NeoplasmsMolecular dynamicsQM/MMBreast cancerbreast cancerDrug DiscoverymedicineHumansAromataseIC50Pharmacologychemistry.chemical_classificationbiologyAromatase InhibitorsMultitargetOrganic ChemistryEstrogen AntagonistsAromatase inhibitorGeneral Medicinemedicine.diseaseSERMEnzymechemistryEstrogenCell cultureSettore CHIM/03 - Chimica Generale E InorganicaSERDbiology.proteinCancer researchFemale
researchProduct

Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.

2019

Estrogens play a key role in cellular proliferation of estrogen-receptor-positive (ER+) breast cancers (BCs). Suppression of estrogen production by competitive inhibitors of the enzyme aromatase (AIs) is currently one of the most effective therapies against ER + BC. Yet, the development of acquired resistance, after prolonged treatments with AIs, represents a clinical major concern. Serendipitous findings indicate that aromatase may be non-competitively inhibited by clinically employed drugs and/or industrial chemicals. Here, by performing in silico screening on two putative allosteric sites, molecular dynamics and free energy simulations, supported by enzymatic and cell-based assays, we id…

Molecular dynamicmedicine.drug_classIn silicoAllosteric regulationCytochromes P450; Aromatase; Molecular dynamics; Aromatase inhibitors; Docking; Breast cancer; Resistance onset; Mixed inhibition mechanismAntineoplastic AgentsBreast NeoplasmsMolecular dynamicsMolecular Dynamics SimulationDockingStructure-Activity RelationshipBreast cancerBreast cancerAromataseAllosteric RegulationCell Line TumorDrug DiscoverymedicineResistance onsetHumansMixed inhibition mechanismAromataseEnzyme InhibitorsCell ProliferationPharmacologychemistry.chemical_classificationbiologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryRational designAromatase inhibitorGeneral Medicinemedicine.diseaseEnzymeAromatase inhibitorsSettore CHIM/03 - Chimica Generale E InorganicaEstrogenDocking (molecular)Drug Designbiology.proteinCancer researchDrug Screening Assays AntitumorCytochromes P450European journal of medicinal chemistry
researchProduct

Design, synthesis and biological evaluation of novel stilbene-based antitumor agents

2008

A series of novel stilbene derivatives has been synthesized and studied with the main goal to investigate SAR of the amino compound 1a, as well as to improve its water solubility, a potentially negative aspect of the molecule that could be a serious obstacle for a pre-clinical development. We have obtained derivatives with good cytotoxic activity, in particular, the derivatives 5c and 6b could represent two novel leads for further investigation. Compound 8b, a morpholino-carbamate derivative, prodrug of 1a, has a very good solubility in water, and is active in suppressing growth of tumor cells at a concentration of 5000 nM, which is a concentration 100 times higher than the parent stilbene …

Molecular modelClinical BiochemistryAntitumor agents; Prodrugs; Stilbenes;Pharmaceutical ScienceAntineoplastic AgentsBiochemistryChemical synthesisStructure-Activity RelationshipTubulinCell Line TumorStilbenesDrug DiscoveryHumansMoleculeOrganic chemistryProdrugsAminesSolubilityMolecular BiologyCell Proliferationchemistry.chemical_classificationAqueous solutionDose-Response Relationship DrugOrganic ChemistryAromatic amineProdrugCombinatorial chemistryIn vitroSolubilitychemistryDrug DesignMolecular MedicineBioorganic & Medicinal Chemistry
researchProduct

Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice.

2008

SLC5A8 is a member of the sodium/glucose cotransporter family. It has been proposed that SLC5A8 might act as an apical iodide transporter in the thyroid follicular cells or as a transporter of short chain monocarboxylates. We have directly addressed the functional role of SLC5A8 in vivo by generation of SLC5A8 mutant mice. We found that SLC5A8 is responsible for the re-absorption of lactate at the apical membrane of the kidney proximal tubules and of serous salivary gland ducts. In addition, SLC5A8 mediated the uptake of lactate into colonocytes under physiological conditions. We did not find any evidence of SLC5A8 being essential for the apical iodide transport in the thyroid gland, even i…

Monocarboxylic Acid Transportersmedicine.medical_specialtyColonButyrateBiologyBiochemistryIntestinal absorptionMiceInternal medicinemedicineAnimalsIodide transportLactic AcidMolecular BiologyCation Transport ProteinsMice KnockoutThyroidSodiumTransporterCell BiologyNeoplasms ExperimentalApical membraneTransport proteinButyratesMembrane Transport Structure Function and BiogenesisEndocrinologymedicine.anatomical_structureCell Transformation NeoplasticIntestinal AbsorptionCarcinogensKidney DiseasesCotransporterThe Journal of biological chemistry
researchProduct

Ramucirumab and its use in gastric cancer treatment

2014

Abstract: The inhibition of the mechanisms of tumor neo-angiogenesis represents a milestone that in the last 10 years has seen the advent of numerous molecules to target action against the vascular endothelial growth factor (VEGF). More recently, new molecules have been developed that inhibit tumor spread by the blockade of specific VEGF receptors (VEGFRs), thereby preventing the binding of a ligand to its receptor and the cascade of proliferative events downstream. Ramucirumab is a fully humanized IgG1 monoclonal antibody that performs its action by blocking the isoform 2 of the VEGF receptor (VEGFR-2). Numerous preclinical and clinical studies have demonstrated its activity in several sol…

Monoclonal antibodyGene isoformmedicine.drug_classAngiogenesisAngiogenesis; Gastroesophageal junction cancer; Metastatic gastric cancer; Monoclonal antibody; Ramucirumab; VEGF receptors; Pharmacology; Pharmacology (medical)Antineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroesophageal junction cancerMonoclonal antibodyRamucirumabRamucirumabchemistry.chemical_compoundStomach NeoplasmsmedicineHumansPharmacology (medical)ReceptorVEGF receptorsPharmacologyClinical Trials as Topicbusiness.industryPharmacology. TherapyVEGF receptorAntibodies MonoclonalLigand (biochemistry)Vascular Endothelial Growth Factor Receptor-2BlockadeVascular endothelial growth factorAngiogenesichemistryAngiogenesisbusinessMetastatic gastric cancerDrugs of Today
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct